Researchers from the Human Protein Atlas are planning a clinical trial of a new treatment for nonalcoholic fatty liver disease and type 2 diabetes which harnesses liver cells own ability to burn accumulated fats...Read more
Adil Mardinoglu is a SciLifeLab fellow and the newest addition to the Protein Atlas team of principal investigators. He is the leader of the systems biology group, a group that create biological networks to identify drug targets and discover biomarkers for the development of efficient treatment strategies.
But Adil´s background is not in medicine, he is an electronic engineer with a PhD in computational biology.
– I did my PhD in Ireland where I worked with magnetic drug targeting, he says.
After a one year post doc doing research on neuronal networks, Adil Mardinoglu moved to Chalmers in Gothenburg to join Jens Nielsens group in systems biology...Read more
In a paper in a recent issue of Cell Metabolism, Human Protein Atlas-researchers investigate the biological processes that are altered in obese subjects.
Obesity is associated with an increased risk for a wide range of morbidities, including insulin resistance, type 2 diabetes, non-alcoholic fatty liver disease, and cardiovascular disease. Although the prevalence of obesity continues to dramatically increase worldwide, a clear understanding of the underlying molecular mechanisms involved in the progression of associated disorders is still lacking...Read more
In a recent number of Nature Reviews, Human Protein Atlas researchers Mathias Uhlén and Adil Mardinoglu discuss a study by E.G. Williams and co workers in Science where five complementary -omics datasets across various environmental states (including genomics, transcriptomics, proteomics, metabolomics and phenomics) using the liver as a platform for multiomics analysis are integrated...Read more
Last week, researchers from the Human Protein Atlas, together with others, published a study on drug-induced liver injury in the journal Liver International.
Drug-induced liver injury is the single leading cause for termination of drug development and safety-related withdrawal of approved drugs from the market. In clinical practice, it accounts for more than 50% of liver failure cases and represents a major safety issue for patients. In some patients, drug-induced liver injury can cause severe injury leading to acute liver failure that can be life threatening and require liver transplantation...Read more
February 28, 2018 - March 2, 2018
The Wellcome Genome Campus organizes the conference Proteomics in Cell Biology and Disease Mechanisms where Dr. Emma Lundberg will present "Dissecting the spatiotemporal subcellular distribution of the human proteome". Her talk is scheduled on March 2. Draft programme